Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium.

2.50
Hdl Handle:
http://hdl.handle.net/11287/618023
Title:
Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium.
Authors:
Koivula, R. W.; Heggie, A.; Barnett, A.; Cederberg, H.; Hansen, T. H.; Koopman, A. D.; Ridderstråle, M.; Rutters, F.; Vestergaard, H.; Gupta, R.; Herrgård, S.; Heymans, M. W.; Perry, Mandy ( 0000-0003-4303-2718 ) ; Rauh, S.; Siloaho, M.; Teare, H. J. A.; Thorand, B.; Bell, J.; Brunak, S.; Frost, G.; Jablonka, B.; Mari, A.; McDonald, Timothy J. ( 0000-0003-3559-6660 ) ; Dekker, J. M.; Hansen, T. V. O.; Hattersley, Andrew T.; Laakso, M.; Pedersen, O.; Koivisto, V.; Ruetten, H.; Walker, M.; Pearson, E. R.; Franks, P. W.
Abstract:
The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarkers that: (1) predict the rate of glycaemic deterioration before and after type 2 diabetes onset; (2) predict the response to diabetes therapies; and (3) help stratify type 2 diabetes into clearly definable disease subclasses that can be treated more effectively than without stratification. This paper describes two new prospective cohort studies conducted as part of DIRECT.
Citation:
Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. 2014, 57 (6):1132-42 Diabetologia
Publisher:
Springer
Journal:
Diabetologia
Issue Date:
Jun-2014
URI:
http://hdl.handle.net/11287/618023
DOI:
10.1007/s00125-014-3216-x
PubMed ID:
24695864
Additional Links:
http://dx.doi.org/10.1007/s00125-014-3216-x
Note:
This article is freely available via Open Access. Click on the 'Additional Link' above to access the full-text via the publisher's site.
Type:
Journal Article; Research Support, Non-U.S. Gov't
Language:
en
ISSN:
1432-0428
Appears in Collections:
2014 RD&E publications; Diabetes/Endocrine Services; Exeter Clinical Laboratory International (Blood Sciences, Genetics, Cellular Pathology & Microbiology)

Full metadata record

DC FieldValue Language
dc.contributor.authorKoivula, R. W.en
dc.contributor.authorHeggie, A.en
dc.contributor.authorBarnett, A.en
dc.contributor.authorCederberg, H.en
dc.contributor.authorHansen, T. H.en
dc.contributor.authorKoopman, A. D.en
dc.contributor.authorRidderstråle, M.en
dc.contributor.authorRutters, F.en
dc.contributor.authorVestergaard, H.en
dc.contributor.authorGupta, R.en
dc.contributor.authorHerrgård, S.en
dc.contributor.authorHeymans, M. W.en
dc.contributor.authorPerry, Mandyen
dc.contributor.authorRauh, S.en
dc.contributor.authorSiloaho, M.en
dc.contributor.authorTeare, H. J. A.en
dc.contributor.authorThorand, B.en
dc.contributor.authorBell, J.en
dc.contributor.authorBrunak, S.en
dc.contributor.authorFrost, G.en
dc.contributor.authorJablonka, B.en
dc.contributor.authorMari, A.en
dc.contributor.authorMcDonald, Timothy J.en
dc.contributor.authorDekker, J. M.en
dc.contributor.authorHansen, T. V. O.en
dc.contributor.authorHattersley, Andrew T.en
dc.contributor.authorLaakso, M.en
dc.contributor.authorPedersen, O.en
dc.contributor.authorKoivisto, V.en
dc.contributor.authorRuetten, H.en
dc.contributor.authorWalker, M.en
dc.contributor.authorPearson, E. R.en
dc.contributor.authorFranks, P. W.en
dc.date.accessioned2016-08-08T10:29:54Z-
dc.date.available2016-08-08T10:29:54Z-
dc.date.issued2014-06-
dc.identifier.citationDiscovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. 2014, 57 (6):1132-42 Diabetologiaen
dc.identifier.issn1432-0428-
dc.identifier.pmid24695864-
dc.identifier.doi10.1007/s00125-014-3216-x-
dc.identifier.urihttp://hdl.handle.net/11287/618023-
dc.description.abstractThe DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarkers that: (1) predict the rate of glycaemic deterioration before and after type 2 diabetes onset; (2) predict the response to diabetes therapies; and (3) help stratify type 2 diabetes into clearly definable disease subclasses that can be treated more effectively than without stratification. This paper describes two new prospective cohort studies conducted as part of DIRECT.en
dc.language.isoenen
dc.publisherSpringeren
dc.relation.urlhttp://dx.doi.org/10.1007/s00125-014-3216-xen
dc.rightsArchived with thanks to Diabetologiaen
dc.subjectWessex Classification Subject Headings::Oncology. Pathology.::Geneticsen
dc.subjectWessex Classification Subject Headings::Endocrinology::Diabetesen
dc.titleDiscovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium.en
dc.typeJournal Articleen
dc.typeResearch Support, Non-U.S. Gov'ten
dc.identifier.journalDiabetologiaen
dc.description.noteThis article is freely available via Open Access. Click on the 'Additional Link' above to access the full-text via the publisher's site.en
dc.type.versionPublisheden
All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.